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ABSTRACT
Background Cancer seems to have an independent 
adverse prognostic effect on COVID-19- related mortality, 
but uncertainty exists regarding its effect across different 
patient subgroups. We report a population- based analysis 
of patients hospitalised with COVID-19 with prior or current 
solid cancer versus those without cancer.
Methods We analysed data of adult patients registered 
until 24 May 2020 in the Belgian nationwide database of 
Sciensano. The primary objective was in- hospital mortality 
within 30 days of COVID-19 diagnosis among patients with 
solid cancer versus patients without cancer. Severe event 
occurrence, a composite of intensive care unit admission, 
invasive ventilation and/or death, was a secondary objective. 
These endpoints were analysed across different patient 
subgroups. Multivariable logistic regression models were 
used to analyse the association between cancer and clinical 
characteristics (baseline analysis) and the effect of cancer 
on in- hospital mortality and on severe event occurrence, 
adjusting for clinical characteristics (in- hospital analysis).
Results A total of 13 594 patients (of whom 1187 with solid 
cancer (8.7%)) were evaluable for the baseline analysis and 
10 486 (892 with solid cancer (8.5%)) for the in- hospital 
analysis. Patients with cancer were older and presented 
with less symptoms/signs and lung imaging alterations. The 
30- day in- hospital mortality was higher in patients with solid 
cancer compared with patients without cancer (31.7% vs 
20.0%, respectively; adjusted OR (aOR) 1.34; 95% CI 1.13 
to 1.58). The aOR was 3.84 (95% CI 1.94 to 7.59) among 
younger patients (<60 years) and 2.27 (95% CI 1.41 to 3.64) 
among patients without other comorbidities. Severe event 
occurrence was similar in both groups (36.7% vs 28.8%; 
aOR 1.10; 95% CI 0.95 to 1.29).
Conclusions This population- based analysis demonstrates 
that solid cancer is an independent adverse prognostic factor 
for in- hospital mortality among patients with COVID-19. 
This adverse effect was more pronounced among younger 
patients and those without other comorbidities. Patients with 
solid cancer should be prioritised in vaccination campaigns 
and in tailored containment measurements.
INTRODUCTION
The betacoronavirus severe acute respiratory 
syndrome coronavirus-2 (SARS- CoV-2), causing 
the disease COVID-19, was first detected in 
Wuhan, China, by the end of 2019 and has 
Key questions
What is already known about this subject?
 ► Cancer seems to have an independent adverse 
prognostic effect on COVID-19- related mortality, but 
uncertainty exists regarding its effect across differ-
ent patient subgroups. This knowledge is necessary, 
in order to provide tailored healthcare management 
to these patients.
What does this study add?
 ► In this population- based nationwide cohort study, 
we observed that hospitalised patients with solid 
cancer and COVID-19 were older and presented 
with fewer symptoms/signs and lung imaging al-
terations compared with patients without cancer. 
Moreover, hospitalised patients with solid cancer 
had a 34% higher chance of dying within 30 days of 
COVID-19 diagnosis compared with patients with-
out cancer. This adverse prognostic effect was more 
pronounced among patients <60 years and/or those 
without other comorbidities.
How might this impact on clinical practice?
 ► We demonstrate that solid cancer is an independent 
adverse prognostic factor for 30- day in- hospital 
mortality among patients with COVID-19, especially 
among those with a favourable baseline prognosis. 
Patients with solid cancer should be prioritised in 
vaccination campaigns and in tailored containment 
measurements and clinicians should be aware of 
this adverse prognostic effect when discussing 
cancer treatment plans, in case a new surge of 
COVID-19 cases is seen in their region.
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spread across the world.1 The first case in Belgium was iden-
tified on 15 February 2020 and as of 6 August 2020, 70 555 
cases of COVID-19 and 9852 deaths have been reported in 
the country.2 The first reports from China raised concerns 
regarding a possible higher risk and worse outcome of 
COVID-19 among patients with cancer.3 4 In a cohort of 
over 20 000 patients hospitalised with COVID-19 in the UK, 
10% had a malignancy and their adjusted HR for hospital 
death was 1.13 compared with patients without cancer (95% 
CI 1.02 to 1.24).5 In another report including 928 patients 
with cancer and COVID-19, 30- day mortality was 13% and 
independent adverse prognostic factors were advanced age, 
male gender, being a former smoker, number of comorbid-
ities, Eastern Cooperative Oncology Group performance 
status of ≥2 and having an active cancer.6
Notwithstanding these findings, more data are urgently 
needed to explore the vulnerability of patients with cancer 
during the COVID-19 pandemic and to provide tailored 
healthcare management to this population. We performed 
a population- based nationwide analysis among patients 
hospitalised with COVID-19 in Belgium, to investigate the 
baseline characteristics, clinical presentation and outcomes 
of patients with a solid cancer compared with patients 




We analysed an anonymised subset of data from the nation-
wide population- based surveillance database of the Belgian 
public health institute Sciensano.7 8 As part of its mission 
of national surveillance of infectious diseases, Sciensano 
collects/retrieves data from records of patients hospitalised 
with COVID-19, in particular patient demographics, comor-
bidities (including history of solid cancer), clinical pres-
entation and outcomes. For each subject, data are captured 
at admission and at discharge/death through two different 
questionnaires. Although completion of these question-
naires is not mandatory, the database contains informa-
tion on more than 70% of all patients hospitalised with 
COVID-19 in Belgium and is completed by more than 100 
hospitals (figure 1). Data from Sciensano was shared with 
the Belgian Society of Medical Oncology on 26 May 2020 
through a secured data transfer platform applying data 
encryption. The data set contained information collected 
until 24 May 2020.
Patient population
Information on demographics, comorbidities, clinical 
presentation at hospital admission/COVID-19 diagnosis, 
method of COVID-19 diagnosis, administered treatments, 
clinical evolution and outcomes were included in this 
analysis. Adults (individuals ≥18 years) for whom prior or 
current solid cancer was reported were included in the 
cancer group and those without a history of solid or haema-
tological malignancy were included in the non- cancer 
group. Diagnosis of COVID-19 was based on a molecular 
test (PCR or antigen test) and/or suggestive imaging alter-
ations on chest CT scan combined with typical clinical pres-
entation of COVID-19.
Analysis overview
Our primary objective was to compare in- hospital mortality 
within 30 days of COVID-19 diagnosis among patients with 
solid cancer versus those without cancer, adjusted for clin-
ical characteristics. In addition, we compared baseline char-
acteristics, clinical and imaging manifestations of COVID-
19, clinical evolution and treatments administered during 
hospitalisation between the two groups. We also evaluated 
the occurrence of a severe event, a composite of intensive 
care unit (ICU) admission, invasive ventilation use and/
or death. Baseline characteristics and presentation of 
COVID-19 were assessed in the entire population (base-
line analysis), while clinical evolution, 30- day in- hospital 
mortality and severe event occurrence were only evaluated 
among patients with discharge data (in- hospital analysis). 
This study is reported according to the Strengthening 
the Reporting of Observational Studies in Epidemiology 
(STROBE) statement.9
Statistical analysis
Categorical variables were shown as frequencies with 
percentages and continuous variables as medians with IQR 
or means with SD. Baseline patient characteristics, clinical 
presentation, evolution and COVID-19- directed treatments 
during hospitalisation were compared between the two 
groups using χ2 or Fisher’s exact tests for categorical vari-
ables and Mann- Whitney U or two- sample t- tests for contin-
uous variables. Multivariable logistic regression models were 
used to analyse the association of solid cancer with base-
line characteristics and clinical/imaging manifestations of 
COVID-19, while correcting for age and gender (baseline 
analysis); and with clinical evolution and treatments admin-
istered during hospitalisation, adjusting for age, gender, 
comorbidities and the use of renin- angiotensin- aldosterone 
system inhibitors (RAASi) at the time of COVID-19 diag-
nosis (in- hospital analysis). Results are reported as ORs 
with 95% CI. A sensitivity analysis was performed excluding 
patients with symptom onset after admission (ie, who were 
hospitalised due to other reasons and were diagnosed with 
COVID-19 during hospitalisation).
A multivariable logistic regression analysis was performed 
to assess the effect of cancer on 30- day all- cause in- hospital 
mortality and severe event occurrence, adjusting for age, 
gender, comorbidities and RAASi use. These analyses were 
performed for patients with discharge data, overall and 
across patient subgroups. Baseline characteristics with a 
missingness ≥10% were not included in the multivariable 
model and a complete case analysis was performed. All 
tests were two- sided and results with a p value <0.05 were 
considered statistically significant. Given the exploratory 
nature of the secondary and subgroup analyses, no multiple 
testing correction was applied. Analyses were carried out 
in SAS V.3.8 statistical software (SAS Institute Inc, Cary, 
North Carolina, USA). Detailed information regarding the 
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statistical analysis is provided in the online supplemental 
methods and online supplemental table 1.
RESULTS
Baseline analysis
On 24 May 2020, 57 342 individuals had a laboratory- 
confirmed diagnosis of COVID-19 in Belgium, of whom 17 
052 were or had been hospitalised. From 3 April 2020 on, 
CT scan- confirmed cases were also included in the Sciensano 
database, and by 24 May 2020, 15 378 hospitalised patients 
with laboratory- confirmed or CT- confirmed COVID-19 had 
data recorded in the database. We excluded 1313 patients 
without admission data, 239 subjects <18 years old and 232 
patients with haematological malignancies (without a solid 
tumour). A total of 13 594 patients were evaluable for the base-
line analysis (12 407 patients without and 1187 patients with 
cancer) and 10 486 for the in- hospital analysis (9594 patients 
without and 892 patients with cancer) (figure 1). Patients 
included in the in- hospital analysis were admitted earlier in 
time and were slightly younger than patients without avail-
able discharge data (mean 67.8 vs 70.1 years, respectively), 
but there were no significant differences regarding gender 
and most comorbidities (online supplemental figure 1 and 
online supplemental table 2). Diagnosis of COVID-19 was 
based on molecular testing in 12 446 patients (91.6%) and on 
imaging and clinical findings in 1038 patients (7.6%), while 
diagnostic modality was unknown for 110 patients (0.8%).
Patients with cancer were older and more frequently were 
men compared with patients without cancer. When adjusting 
for age and gender, patients with cancer had more chronic 
lung and liver diseases, were more often considered immuno-
suppressed, more likely to be current smokers and had more 
Figure 1 Flowchart of included patients up to 24 May 2020. aTotal number of new hospitalisations between 15 February 
2020 and 24 May 2020 of patients with laboratory- confirmed COVID-19 at the moment of reporting and that were not referred 
from another hospital. bAmong these patients, 1313 did not have data on the admission questionnaire and, therefore, there 
was no information on the diagnostic method, as the method was only asked in the admission questionnaire; these patients 
were excluded from both baseline and in- hospital analysis. cUnavailability of discharge data may be due to different reasons: 
(I) the patient was still hospitalised at the time of data transfer; (II) the patient had already been discharged, but the discharge 
questionnaire had not yet been filled; and (III) the patient had already been discharged, the discharge questionnaire had been 
filled, but it could not be linked to the admission questionnaire (eg, due to errors on the insertion of the patient’s identifying 
information).
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frequently received influenza vaccination compared with 
patients without cancer (table 1). Results were similar among 
the subset of patients with both admission and discharge data 
(online supplemental table 3).
Patients with cancer were less likely to present with systemic, 
respiratory or neurological symptoms, temperature ≥38°C, 
respiratory signs or abnormalities consistent with COVID-19 
on imaging. Overall, a higher proportion of patients with 
cancer were asymptomatic or had no signs at presentation 
compared with patients without cancer (8.4% vs 5.5%, and 
16.6% vs 12.4%, respectively) (table 1 and online supple-
mental table 4). As patients with solid cancer had a higher 
likelihood of being diagnosed with COVID-19 while already 
hospitalised, we performed a sensitivity analysis excluding 
these patients, which showed similar findings (online supple-
mental table 5).
In-hospital analysis
Among the 10 486 patients with available discharge data, 
patients with cancer more frequently received corticosteroids 
during hospitalisation, but were less likely to receive COVID-
19- directed treatment (table 2). Compared with patients 
without cancer, patients with solid cancer were less frequently 
admitted to an ICU (13.2% vs 8.6%, respectively; adjusted 
OR 0.70; 95% CI 0.55 to 0.90) and less likely to receive inva-
sive ventilation (8.1% vs 4.9%, respectively; adjusted OR 0.67; 
95% CI 0.49 to 0.93).
As of 24 May 2020, 2205 (21.0%) patients had died in the 
hospital within 30 days of COVID-19 diagnosis. After adjust-
ment for age, gender, comorbidities and RAASi use, hospi-
talised patients with solid cancer had a higher likelihood 
of dying within 30 days of COVID-19 diagnosis compared 
with patients without cancer (31.7% vs 20.0%; adjusted OR 
1.34; 95% CI 1.13 to 1.58). The effect of cancer on 30- day 
in- hospital mortality seemed to be more pronounced among 
younger patients (<60 years; 12.4% mortality in patients with 
cancer vs 3.2% in patients without cancer; adjusted OR 3.84; 
95% CI 1.94 to 7.59) and patients without other comorbidi-
ties (20.9% vs 6.1%, respectively; adjusted OR 2.27; 95% CI 
1.41 to 3.64) (figure 2 and online supplemental table 6). 
Regarding the composite endpoint of 30- day severe event 
occurrence, there were no significant differences between 
patients with or without cancer either in the overall popula-
tion (36.7% vs 28.8%, respectively; adjusted OR 1.10; 95% CI 
0.95 to 1.29) or across most subgroups (figure 3 and online 
supplemental table 7).
DISCUSSION
We report a population- based nationwide analysis of the clin-
ical course, treatment and outcomes of hospitalised patients 
with COVID-19 with prior or current solid cancer compared 
with patients without cancer. Patients with solid cancer 
comprised 8.7% of hospitalised patients with COVID-19 in 
Belgium and they were older, presented with fewer symptoms, 
signs and lung imaging alterations and were more likely to 
receive corticosteroids during hospitalisation compared with 
patients without cancer. In- hospital 30- day mortality among 
patients with solid cancer was 31.7% compared with 20.0% 
in the non- cancer group. After adjustment, patients with a 
solid malignancy had a 34% higher likelihood of in- hospital 
death within 30 days of COVID-19 diagnosis compared with 
patients without cancer. The effect of cancer on in- hospital 
mortality was more pronounced among patients <60 years 
of age and/or without other comorbidities. However, there 
were no differences regarding severe event occurrence, 
mainly due to the lower likelihood of ICU admission among 
patients with cancer.
This is a large population- based analysis including over 
1000 patients with cancer, hospitalised for COVID-19 in both 
academic and non- academic hospitals in Belgium, for whom 
data was systematically registered into a public institutional 
database. Compared with registries with post hoc patient 
identification and data collection, this methodology is far less 
prone to recall and selection bias. Nonetheless, no details on 
cancer characteristics and anticancer treatments were avail-
able in the database. Yet, the probable inclusion of patients 
with prior cancer in the cancer group implies an underesti-
mation of the adverse prognostic impact of current cancer 
on in- hospital mortality and, therefore, our study provides 
conservative estimates of its effect.
Since the Sciensano database only included hospitalised 
patients, we did not capture the full spectrum of COVID-19 
manifestations and outcomes among patients with solid 
cancer. We assume that the likelihood of undergoing 
SARS- CoV-2 screening when paucisymptomatic or asymp-
tomatic is higher in patients with cancer compared with 
the non- cancer group. However, even though the majority 
of these patients with a positive SARS- CoV-2 test were not 
admitted, differences in admission thresholds may have led 
to the higher proportion of admissions of less symptom-
atic patients in the cancer group. Moreover, patients with 
cancer may experience chronic symptoms that overlap with 
COVID-19 symptoms (eg, cough, fatigue) and thus do not 
report them. Nonetheless, despite being less symptomatic, 
patients with solid cancer still had a higher likelihood of 
in- hospital mortality compared with the non- cancer group 
and this effect was independent of the number/type of 
signs/symptoms at diagnosis (data not shown).
We were unable to include patients without discharge 
data in the in- hospital analysis as information regarding 
their current vital status is lacking. Nevertheless, we showed 
that despite being slightly older, there were no other major 
baseline differences compared with patients with discharge 
data. Additionally, we used the 30- day mortality outcome in 
order to limit the possible bias of excluding patients with 
long- duration hospitalisations. Given the rapid pace of 
new evidence, the Sciensano questionnaire was amended 
since its implementation in 14 March 2020. Some variables 
such as ‘obesity’ and ‘other comorbidities’ were introduced 
later, resulting in a significant proportion of missing data 
for these variables. For others, such as smoking status, a 
high number of unknown answers precluded its use in the 
multivariable model. Nonetheless, when further adjusting 
our model for smoking status and obesity in the group of 
patients with available data, the increased likelihood of 
Open access
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Table 1 Baseline characteristics and COVID-19 clinical presentation of patients included in the baseline analysis (n=13 594)
Patients without 
cancer (n=12 407)
Patients with solid 
cancer (n=1187) P value*
Adjusted OR (95% 
CI)†
Age, in years
  Mean (SD) 67.7 (17.1) 74.5 (11.8) <0.001 --
  Median (IQR) 70 (55 to 82) 75 (67 to 83)
Age, in years - n (%)
  <50 1952 (15.7) 34 (2.9) <0.001 1
  50–59 2002 (16.4) 97 (8.2) 2.83 (1.90 to 4.22)
  60–69 2139 (17.2) 240 (20.2) 6.55 (4.53 to 9.48)
  70–79 2463 (19.9) 369 (31.1) 8.78 (6.12 to 12.60)
  80–89 2976 (19.9) 343 (28.9) 4.82 (4.75 to 9.79)
  ≥90 875 (7.1) 104 (8.8) 7.08 (4.74 to 10.56)
Gender - n (%)
  Female 5777 (46.9) 528 (44.8) 0.16 1
  Male 6529 (53.1) 55.2 (54.8) 1.20 (1.06 to 1.63)
  Missing 101 8
Comorbidities (presence) - n (%)
  Cardiovascular disease 4182 (33.7) 497 (41.9) <0.001 1.00 (0.88 to 1.14)
  Hypertension 4931 (39.7) 511 (43.1) 0.03 0.89 (0.79 to 1.01)
  Diabetes 2705 (21.8) 269 (22.7) 0.49 0.94 (0.81 to 1.09)
  Chronic kidney disease 1548 (12.5) 188 (15.8) 0.001 1.00 (0.84 to 1.18)
  Chronic liver disease 309 (2.5) 52 (4.4) <0.001 1.90 (1.41 to 2.58)
  Chronic lung disease 1777 (14.3) 261 (22.0) <0.001 1.55 (1.33 to 1.80)
  Chronic neurological disease 1099 (8.9) 112 (9.4) 0.49 0.93 (0.76 to 115)
  Cognitive disorder 1441 (11.7) 119 (10.1) 0.11 0.61 (0.50 to 0.75)
  Missing 62 5
  Immunosuppression, including HIV 254 (2.1) 64 (5.4) <0.001 3.32 (2.49 to 4.42)
  Haematological cancer 0 30 (2.5) <0.001 NC
  Pregnancy 102 (0.8) 0 0.002 NC
  Postpartum (<6 weeks) 15 (0.1) 0 0.64 NC
  Obesity 822 (10.4) 61 (7.1) 0.002 0.87 (0.66 to 1.13)
  Missing 4533 326
  Other comorbidities 1017 (14.1) 89 (11.2) 0.02 0.97 (0.77 to 1.22)
  Missing 5207 389
  No comorbidities‡ 3019 (24.3) 221 (18.6) <0.001 0.93 (0.79 to 1.10)
Number of comorbidities‡ - n (%)
  0 3019 (24.3) 221 (18.6) <0.001 1
  1 3518 (28.4) 295 (24.9) 0.87 (0.72 to 1.05)
  2 2787 (22.5) 294 (24.8) 0.93 (0.77 to 1.13)
  ≥3 3083 (24.9) 377 (31.8) 1.01 (0.83 to 1.22)
Current smoker - n (%)
  No 5936 (47.8) 569 (47.9) <0.001 1
  Yes 660 (5.3) 100 (8.4) 1.87 (1.48 to 2.36)
  Unknown 5811 (46.8) 518 (43.6) 0.93 (0.82 to 1.06)
Influenza vaccination (2019/2020 season) - n (%)
  No 913 (7.4) 43 (3.6) <0.001 1
Continued
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30- day in- hospital death among cancer patients was main-
tained (data not shown).
Our findings are consistent with other reports comparing 
COVID-19 characteristics and outcomes in patients with and 
without cancer. In the above mentioned cohort of over 20 
000 patients hospitalised with COVID-19 in the UK, patients 
with cancer had an increase of 13% in the likelihood of 
dying.5 In a larger database comprising both hospitalised 
and non- hospitalised patients (the OpenSAFELY platform), 
patients with active cancer had higher mortality, with a HR 
that ranged from 1.72 (95% CI 1.50 to 1.96) for patients 
diagnosed with cancer <1 year ago to 1.15 (95% CI 1.05 
to 1.27) for patients diagnosed 1 to 5 years ago and 0.96 
(95% CI 0.91 to 1.03) among those diagnosed ≥5 years ago, 
compared with patients without cancer.10 However, none 
of these studies reported on the baseline characteristics, 
COVID-19 presentation or evolution of patients with cancer 
compared with those without cancer. Other reports also 
comprised both hospitalised and non- hospitalised patients, 
but only included patients with cancer. In a more recent 
report of the COVID-19 and Cancer Consortium, among 
2186 cancer patients the 30- day mortality was 16%, but only 
half of patients had been admitted, explaining differences 
in mortality compared with cohorts limited to hospitalised 
patients.11 A mortality rate of 33% was reported among 428 
patients with thoracic cancer, of whom 76% were hospital-
ised.12 Prior administration of chemotherapy was associated 
with increased risk of death, while immunotherapy and tyro-
sine kinase inhibitor use were not. In another report with 
800 patients with cancer and symptomatic COVID-19 hospi-
talised in cancer centres in the UK, mortality was 28% and 
appeared to be mainly driven by age, gender and comor-
bidities.13 These poor prognostic factors were confirmed by 
the OnCovid registry, comprising 890 patients, mostly from 
Italy, Spain and the UK.14 In our report, we compared the 
clinical presentation, evolution and outcomes of COVID-19 
between patients with and without solid cancer within a 
nationwide population- based cohort, without any a priori 
matching. In addition, we evaluated the prognostic effect of 
cancer among different patient subgroups, allowing a more 
Patients without 
cancer (n=12 407)
Patients with solid 
cancer (n=1187) P value*
Adjusted OR (95% 
CI)†
  Yes 825 (6.7) 94 (7.9) 1.88 (1.28 to 2.42)
  Unknown 10 669 (86.0) 1050 (88.5) 1.76 (1.28 to 2.75)
RAASi use - n (%)
  No/unknown 9479 (76.4) 867 (73.0) 0.01 1
  Yes 2928 (23.6) 320 (27.0) 1.00 (0.87 to 1.15)
Timing of symptoms onset - n (%)
  Before or day of hospitalisation 11 680 (94.1) 1030 (86.8) <0.001 1
  During hospitalisation 727 (5.9) 157 (13.2) 2.06 (1.71 to 2.48)
Symptoms at presentation§ - n (%)
  Systemic symptoms 9120 (73.5) 776 (65.4) <0.001 0.75 (0.66 to 0.85)
  Respiratory symptoms 9037 (72.8) 740 (62.3) <0.001 0.70 (0.62 to 0.80)
  Gastrointestinal symptoms 2655 (21.4) 206 (17.4) 0.001 0.87 (0.74 to 1.02)
  Neurological symptoms 2146 (17.3) 143 (12.1) <0.001 0.68 (0.56 to 0.81)
  Pain 2740 (22.1) 208 (17.5) <0.001 0.95 (0.81 to 1.12)
  No symptoms 683 (5.5) 100 (8.4) <0.001 1.46 (1.17 to 1.83)
Signs at presentation¶ - n (%)
  Respiratory signs 10 064 (81.1) 900 (75.8) <0.001 0.76 (0.66 to 0.88)
  Neurological signs 104 (0.8) 9 (0.8) 0.77 0.83 (0.42 to 1.66)
  Temperature ≥38°C (fever) 3717 (30.0) 285 (24.0) <0.001 0.79 (0.68 to 0.90)
  No signs 1534 (12.4) 197 (16.6) <0.001 1.39 (1.18 to 1.64)
*P value for the univariate comparison between the two groups (patients with solid cancer vs without cancer).
†OR for age (as a categorical variable) was adjusted for gender; OR for gender was adjusted for age (as a continuous variable); all other ORs 
were adjusted for age (as a continuous variable) and gender.
‡Excluding the presence of cancer as a comorbidity.
§Systemic symptoms cluster: presence of fever/chills reported by the patient and/or fatigue; respiratory symptoms cluster: presence of 
cough, sore throat, rhinorrhoea, anosmia and/or shortness of breath; gastrointestinal symptoms cluster: presence of diarrhoea and/or nausea/
vomiting; neurological symptoms cluster: presence of headache and/or irritability/mental confusion.
¶Respiratory signs cluster: presence of pharyngeal exudate, dyspnoea/tachypnoea, abnormal pulmonary auscultation and/or abnormal lung 
imaging; neurological signs cluster: presence of coma and/or convulsions.
NC, not calculable; RAASi, renin- angiotensin- aldosterone system inhibitors.
Table 1 Continued
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Table 2 Patient evolution, treatment and outcomes during hospitalisation, among patients with discharge data (n=10 486)
Patients without 
cancer (n=9594)
Patients with solid 
cancer (n=892) P value*
Adjusted OR (95% 
CI)†
Pneumonia at imaging exam‡ - n (%)
  No 1458 (15.2) 161 (18.1) 0.01 1
  Yes 7679 (80.0) 676 (75.8) 0.83 (0.69 to 1.00)
  Unknown 457 (4.8) 55 (6.2) 1.35 (0.95 to 1.89)
ARDS - n (%)
  No 7808 (81.4) 726 (81.4) 0.22 1
  Yes 1277 (13.3) 108 (12.1) 0.87 (0.70 to 1.08)
  Unknown 509 (5.3) 58 (6.5) 1.06 (0.79 to 1.43)
Drugs received during hospitalisation - n (%)
  Hydroxychloroquine 5523 (57.6) 429 (48.1) <0.001 0.75 (0.65 to 0.87)
  Remdesivir 7 (0.1) 0 0.42 NC
  Lopinavir/ritonavir 28 (0.3) 2 (0.2) 0.72 0.73 (0.17 to 3.17)
  Tocilizumab 29 (0.3) 2 (0.2) 0.68 1.22 (0.29 to 5.20)
  Azithromycin 809 (8.4) 82 (9.2) 0.45 1.26 (0.99 to 1.62)
  Other antibiotics 464 (4.8) 53 (5.9) 0.15 1.26 (0.93 to 1.71)
  Other antivirals§ 47 (0.5) 2 (0.2) 0.27 0.63 (0.15 to 2.60)
  Corticosteroids 597 (6.2) 89 (10) <0.001 1.31 (1.02 to 1.68)
  Other immunomodulatory drugs¶ 5 (0.1) 1 (0.1) 0.47 3.67 (0.41 to 32.62)
  Anticoagulants 47 (0.5) 5 (0.6) 0.77 0.91 (0.35 to 2.34)
  Other drugs** 92 (1.0) 3 (0.3) 0.06 0.35 (0.11 to 1.10)
  No treatment reported 3770 (39.3) 406 (45.5) 0.47 1.20 (1.04 to 1.39)
COVID-19- directed treatment†† - n (%)
  No 3816 (39.8) 408 (45.7) <0.001 1
  Yes 5778 (60.2) 484 (54.3) 0.84 (0.73 to 0.98)
Transfer to ICU - n (%)
  No 8326 (86.8) 815 (91.4) <0.001 1
  Yes 1268 (13.2) 77 (8.6) 0.70 (0.55 to 0.90)
Use of invasive ventilation - n (%)
  No 8620 (89.9) 818 (91.7) <0.001 1
  Yes 772 (8.1) 44 (4.9) 0.67 (0.49 to 0.93)
  Unknown 202 (2.1) 30 (3.4) 1.41 (0.94 to 2.13)
Severe event occurrence within 30 days of COVID-19 diagnosis - n (%)
  No 6827 (71.2) 565 (63.3) <0.001 1
  Yes 2767 (28.8) 327 (36.7) 1.10 (0.95 to 1.29)
Vital status within 30 days of COVID-19 diagnosis - n (%)
  Alive 7672 (80.0) 609 (68.3) <0.001 1
  Deceased 1922 (20.0) 283 (31.7) 1.34 (1.13 to 1.58)
*P value for the univariate comparison between the two groups (patients with solid cancer vs without cancer).
†ORs adjusted for age (as a continuous variable), gender, all comorbidities (except ‘obesity’ and ‘other comorbidities’) and renin- 
angiotensin- aldosterone system inhibitors use.
‡Includes pneumonia observed at the CT- scan and/or at the thoracic X- ray.
§Other antivirals include acyclovir, atazanavir, favipiravir and oseltamivir.
¶Other immunomodulatory drugs include anakinra (IL- 1Ra), other anti- IL7 antibodies, siltuximab (anti- IL6) and immunoglobulin G.
**Other drugs include vitamins (vitamin C, vitamin D, thiamine, among others), morphine, acetylcysteine, granulocyte colony- stimulating 
factor and anti- histaminics.
††COVID-19- directed treatment includes hydroxychloroquine, remdesivir, lopinavir/ritonavir, tocilizumab, other antivirals, other 
immunomodulatory drugs, corticosteroids and azithromycin.
ARDS, acute respiratory distress syndrome; ICU, intensive care unit; NC, not calculable.
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accurate assessment of the impact of cancer on COVID-19- 
related outcomes.
Different factors may have contributed to the increased 
mortality observed in our study among cancer patients hospi-
talised with COVID-19. Older age, male gender and smoking 
are associated with an increased risk of cancer15 16 and are 
also independent risk factors for adverse outcomes from 
COVID-19.5 Additionally, patients with cancer are more likely 
to have other comorbidities such as chronic lung or liver 
diseases, which were independent adverse prognostic factors 
for COVID-19 mortality (data not shown). Nonetheless, 
after adjustment for age, gender, comorbidities and RAASi 
use, patients with solid cancer still had an increased risk of 
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Figure 2 Forest plot with subgroup analysis of 30- day in- hospital mortality according to the presence of solid cancer among 
patients included in the in- hospital analysis. ORs adjusted for age (as a continuous variable), gender, all comorbidities (except 
‘obesity’ and ‘other comorbidities’) and renin- angiotensin- aldosterone system inhibitors use. Under the ‘cancer’ and ‘non- 
cancer’ columns is the description of the number of events (n) / number of patients in each subgroup (N) within the cancer 
and the non- cancer group, respectively. *Excluding the presence of cancer as a comorbidity. ARDS,acute respiratory distress 
syndrome; GI, gastrointestinal.
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There are multiple justifications for this phenomenon. 
An immunocompromised status due to previous and/or 
current anticancer therapy, corticosteroids, or other immu-
nosuppressive treatments can significantly impact the clin-
ical course, treatment decisions and outcome of COVID-19. 
The cancer- related increase of thromboembolic risk could 
also contribute to COVID-19 severity.17 Since the Sciensano 
database only captured all- cause mortality, it is possible that, 
despite the short duration of hospitalisation, a small propor-
tion of patients with cancer died because of their malignancy 
and not due to COVID-19. Finally, given the worse perfor-
mance status and life- expectancy of some patients with 
cancer receiving palliative anticancer treatments, a substan-
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Figure 3 Forest plot with subgroup analysis of 30- day severe event occurrence according to the presence of solid cancer 
among patients included in the in- hospital analysis ORs adjusted for age (as a continuous variable), gender, all comorbidities 
(except ‘obesity’ and ‘other comorbidities’) and renin- angiotensin- aldosterone system inhibitors use. Under the ‘cancer’ and 
‘non- cancer’ columns is the description of the number of events (n) / number of patients in each subgroup (N) within the 
cancer and the non- cancer group, respectively. *Excluding the presence of cancer as a comorbidity. ARDS, acute respiratory 
distress syndrome; GI, gastrointestinal.
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had a non- resuscitation request. An imbalance in these treat-
ment limitations would be expected between patients with 
and without cancer and this could contribute to the lower 
likelihood of ICU admission among patients with cancer, 
even after adjustment for age, gender and comorbidities.
The magnitude of the association of cancer with in- hos-
pital mortality differed across patient subgroups. Surprisingly, 
this magnitude progressively decreased as the number of 
comorbidities per patient increased or as the age categories 
increased—from an OR of 3.84 among patients <60 years to 
an OR of 0.98 among those with ≥80 years. Older adults with 
cancer are expected to have a higher proportion of prior 
versus current cancer, more indolent cancers (eg, prostate 
cancer, hormone- receptor positive breast cancer) and are 
less likely to receive immunosuppressive anticancer treat-
ments compared with younger patients. In addition, older 
patients with advanced cancer and severe COVID-19 may 
have a lower likelihood of hospitalisation, potentially leading 
to an underestimation of mortality among older patients with 
cancer. Moreover, given the baseline poor COVID-19- related 
prognosis among older patients or among those with several 
comorbidities, the presence of cancer might not significantly 
worsen their prognosis and might have a smaller impact on 
COVID-19- related treatment decisions. On the other hand, 
among patients with a more favourable COVID-19- related 
prognosis (young age and/or absence of other comorbidi-
ties), the presence of cancer might significantly increase the 
risk of death, given the above- mentioned reasons.
The COVID-19 outbreak provoked a dramatic disruption in 
cancer care around the globe, leading to delays in diagnosis, 
treatment and follow- up and to reductions in the intensity 
of cancer treatment.18–20 Additionally, several recommenda-
tions on how to manage cancer care during the COVID-19 
outbreak have been published by oncological societies and 
by national groups, but given the absence of evidence on this 
subject, they are only expert- based.21–23 Therefore, our results 
have implications for clinicians and public health authorities 
and they may inform future recommendations about cancer 
care during the COVID-19 outbreak. We demonstrate that 
patients with solid cancer hospitalised with COVID-19 present 
with less symptoms, which might be due to lower thresholds 
for asymptomatic testing and hospitalisation, but neverthe-
less have higher in- hospital mortality compared with patients 
without cancer. We have also seen that among patients with 
favourable COVID-19- related prognosis (<60 years and/
or without comorbidities), the presence of cancer led to a 
twofold to threefold increase in the likelihood of in- hospital 
death. Thus, clinicians should be aware of this potential 
adverse prognostic effect when discussing cancer treatment 
plans, in case a new surge of COVID-19 cases is seen in their 
region. Moreover, as lockdown strategies are being eased 
around the world and hope for an effective vaccine grows,24 25 
patients with solid cancer should be regarded as a vulnerable 
group for adverse outcomes of COVID-19 and thus be prior-
itised in vaccination campaigns and in tailored containment 
measurements.
Several questions remain unanswered regarding the effect 
of cancer type and anticancer treatments on the risk of severe 
events or death among cancer patients with COVID-19. 
Cancer- specific data is now being collected in a collaborative 
effort with participating oncologists from Belgian hospitals.
In conclusion, in this population- based nationwide analysis 
of hospitalised patients with COVID-19, we demonstrate that 
after adjustment for age, gender, comorbidities and RAASi 
use, patients with solid cancer have an increased likelihood 
of in- hospital death within 30 days of COVID-19 diagnosis 
compared with patients without cancer. This adverse prog-
nostic effect seems to be more pronounced among patients 
<60 years and/or without other comorbidities.
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